Show simple item record

dc.contributor.authorPérez Tejada, Joana
dc.contributor.authorLabaka Etxeberria, Ainitze
dc.contributor.authorVegas Moreno, Oscar
dc.contributor.authorLarraioz, Aitziber
dc.contributor.authorPescador, Ane
dc.contributor.authorArregi Agirre, Amaia ORCID
dc.date.accessioned2024-01-17T08:07:46Z
dc.date.available2024-01-17T08:07:46Z
dc.date.issued2021-03-26
dc.identifier.citationEuropean Journal of Oncology Nursing 52 : (2021) // Art. ID. 101953es_ES
dc.identifier.issn1462-3889
dc.identifier.urihttp://hdl.handle.net/10810/64050
dc.descriptionThe authors would like to thank the women involved in the present study for their participation.es_ES
dc.description.abstractDespite the fact that the prevalence of anxiety and depression in breast cancer survivors is higher than in general female population, the psychobiological substrate of this phenomenon has yet to be elucidated. We aimed to examine the predictive role of peripheral dopamine (DA), noradrenaline (NA), serotonin (5-HT) and kynurenine (KYN) in anxiety and depression among breast cancer survivors. We evaluated 107 women using the Hospital Anxiety and Depression Scale, and monoamine levels were analyzed via high-performance liquid chromatography. High KYN levels predicted both disorders, while low NA and DA predicted anxiety and depressive symptoms, respectively. A negative conditional effect of 5-HT was found for anxiety and depression among younger women only, while being both middle-aged and younger influenced the negative conditional effect of DA on depression. Monoamine variations may render breast cancer survivors more vulnerable to anxiety and depression, with young women being especially vulnerable to the detrimental effect of low DA and 5-HT. Assessing subclinical psychobiological markers allows mental health nurses to identify vulnerable survivors prior to the onset of anxiety and depression, and to adjust nursing interventions accordingly.es_ES
dc.description.sponsorshipThis study was supported by the Basque Government Project: IT757-13 and by the University of Basque Country Projects: GIU18/103.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.subjectbreast cancer survivorses_ES
dc.subjectdepressiones_ES
dc.subjectanxietyes_ES
dc.subjectagees_ES
dc.subjectmonoamineses_ES
dc.titleAnxiety and depression after breast cancer: The predictive role of monoamine levelses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license https://creativecommons.org/licenses/by/4.0/es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.ejon.2021.101953es_ES
dc.identifier.doi10.1016/j.ejon.2021.101953
dc.departamentoesProcesos psicológicos básicos y su desarrolloes_ES
dc.departamentoeuOinarrizko psikologia prozesuak eta haien garapenaes_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as © 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license https://creativecommons.org/licenses/by/4.0/